Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc.
- Market cap
- $4.74M
Your view on CDIO
Overview
What the company does, where it operates, and who runs it.
About Cardio Diagnostics Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Meeshanthini V. Dogan
- Headquarters
- 400 N Aberdeen St, Chicago, IL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Meeshanthini V. Dogan
- Headquarters
- 400 N Aberdeen St, Chicago, IL, US
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cardio Diagnostics Holdings, Inc.. Starting points for Cardio Diagnostics Holdings, Inc.: EPS -$2.19, beta 2.27 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cardio Diagnostics Holdings, Inc.. Trailing twelve-month EPS for Cardio Diagnostics Holdings, Inc. stands at -$2.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Analyst ratings
1 rating- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 |
|---|---|---|---|
| Average estimate | −$19.80 | −$19.80 | −$16.50 |
| Lowest estimate | −$19.80 | −$19.80 | −$16.50 |
| Highest estimate | −$19.80 | −$19.80 | −$16.50 |
| Number of analysts | 1 | 1 | 1 |
| A year ago | −$0.98 | −$0.801 | −$3.711 |
| Growth vs a year ago | −1920.4% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 |
|---|---|---|---|
| Average estimate | $100000.00 | $100000.00 | $25.00M |
| Lowest estimate | $100000.00 | $100000.00 | $25.00M |
| Highest estimate | $100000.00 | $100000.00 | $25.00M |
| Number of analysts | 1 | 1 | 1 |
| A year ago | $2855.00 | $3555.00 | $14825.00 |
| Growth vs a year ago | +3402.6% | +2712.9% | +168534.1% |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cardio Diagnostics Holdings, Inc.. Cardio Diagnostics Holdings, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ADILAdial Pharmaceuticals, Inc. | Healthcare | Biotechnology | $13.3M | ||
| ADXNAddex Therapeutics Ltd | Healthcare | Biotechnology | $4.3M | ||
| BCDABioCardia, Inc. | Healthcare | Biotechnology | $11.9M | ||
| BCLIBrainstorm Cell Therapeutics Inc. | Healthcare | Biotechnology | $6.8M | ||
| CELZCreative Medical Technology Holdings, Inc. | Healthcare | Biotechnology | $3.1M | ||
| IBOImpact BioMedical Inc. | Healthcare | Biotechnology | $52.8M | ||
| MTNBMatinas BioPharma Holdings, Inc. | Healthcare | Biotechnology | $341,620 | ||
| NRSNNeuroSense Therapeutics Ltd. | Healthcare | Biotechnology | $2.4M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| VPROViropro Inc. | Healthcare | OTC | $25,404 | ||
| VRAXVirax Biolabs Group Limited | Healthcare | NASDAQ | $446,402 | ||
| VRCAVerrica Pharmaceuticals Inc. | Healthcare | NASDAQ | $47.1M | ||
| VRCIVerde Science, Inc. | Healthcare | OTC | $239 | ||
| VRDNViridian Therapeutics, Inc. | Healthcare | NASDAQ | $3.4B | ||
| VRPXVirpax Pharmaceuticals, Inc. | Healthcare | NASDAQ | $26,093 | ||
| VRTXVertex Pharmaceuticals Incorporated | Healthcare | NASDAQ | $130.6B | ||
| VRXAVeraxa Biotech Holding AG | Healthcare | NASDAQ | $147.1M | ||
| VRXAWVeraxa Biotech AG | Healthcare | NASDAQ | $667,920 | ||
| SPRCSciSparc Ltd. | Healthcare | NASDAQ | $113,580 | ||
| SPROSpero Therapeutics, Inc. | Healthcare | NASDAQ | $43.2M | ||
| SPRYARS Pharmaceuticals, Inc. | Healthcare | NASDAQ | $297.6M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in CDIO.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Cardio Diagnostics Holdings, Inc., and how their positions are changing. At a $4.7M market value, institutional positions materially move Cardio Diagnostics Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Cardio Diagnostics Holdings, Inc. executives and directors. Shares of Cardio Diagnostics Holdings, Inc. have traded between $2.73 and $53.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Cardio Diagnostics Holdings, Inc.. Coverage tracks Cardio Diagnostics Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cardio Diagnostics Holdings, Inc.